Burlington, Massachusetts, December 11, 2017 — MilliporeSigma today announced that it has entered into an agreement with Avanti® Polar Lipids to be the exclusive multinational distributor of the Alabama-based company’s research lipids portfolio outside of the United States.
Under the terms of the agreement, MilliporeSigma will employ its sales, marketing and e-commerce expertise to distribute Avanti® Polar Lipid’s research lipid portfolio. The distribution agreement includes all geographies worldwide except for the United States, where Avanti® will continue to reach customers via its own channels. Financial details were not disclosed.
“High-quality lipids are an essential component of precision in the laboratory,” said Klaus Bischoff, Head of Research Solutions at MilliporeSigma. “Avanti® Polar Lipids’ research lipids strengthen MilliporeSigma’s overall Life Science portfolio, giving our customers access to a broad portfolio of the highest purity lipids on the market.”
MilliporeSigma offers a complete portfolio of products and solutions that enable scientific discovery, including life science reagents and kits, lab and specialty chemicals and lab separation and workflow tools.
Avanti® Polar Lipids is a leading manufacturer and supplier of the highest purity lipids for research and pharmaceutical product development. Through this agreement, customers outside of the United States will have enhanced, on-demand access to the Avanti® research lipid portfolio through MilliporeSigma’s robust e-commerce platform, SigmaAldrich.com, regional inventory and MilliporeSigma sales representatives. Products will be stocked globally for improved availability to customers.
Transition of approximately 2,000 products from the Avanti® research lipid portfolio to MilliporeSigma is expected to be completed in early 2018. In the interim, these products will continue to be available through existing Avanti® Polar Lipids channels.
Avanti® lipidomics products included in this agreement provide a new approach to answer fundamental questions about lipid structure and function and meet the demands of lipid researchers. For more information, visit www.SigmaAldrich.com/Avanti.
About the Life Science Business of Merck KGaA, Darmstadt, Germany
The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has some 21,000 employees and 59 manufacturing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. Udit Batra is the global chief executive officer of MilliporeSigma.
Merck KGaA, Darmstadt, Germany completed its $17 billion acquisition of Sigma-Aldrich in November 2015, creating a leader in the $125 billion global life science industry.
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 56,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2018, Merck KGaA, Darmstadt, Germany, generated sales of €14.8 billion in 66 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck, KGaA, Darmstadt, Germany, visit www.emdgroup.com.